LXRP - Lexaria expands COVID-19 research for its drug delivery system

After a recent animal study yielded favorable results, Lexaria Bioscience (LXRP) has initiated the next phase of its antiviral drug research program to evaluate the potential of its proprietary drug delivery technology, DehydraTECH™, on COVID-19 infection.The next phase of follow-on studies will assess the potential of its DehydraTECH technology on the delivery and efficacy of additional antiviral drugs, including remdesivir and three additional drugs known to target the main protease associated with SARS-CoV-2 infection.  Conducted by a third-party pharmacokinetic testing laboratory in Pennsylvania, the first study using male Sprague-Dawley rats will quantify and compare total drug delivery into the rodent bloodstream to control formulations.The second study undertaken by a separate third-party laboratory will evaluate the relative antiviral activity of certain Formulations using an established cell culture model of SARS-CoV-2 infected cells to kill the virus. A positive outcome will enable the company to proceed to a larger in vivo efficacy testing

For further details see:

Lexaria expands COVID-19 research for its drug delivery system